Trending

NLRP3

Roche bulks up in inflammation with €380m Inflazome acquisition

Roche bulks up in inflammation with €380m Inflazome acquisition

Roche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory diseases, buying Irish biotech

X

Roche bulks up in inflammation with €380m Inflazome acquisition

https://pharmaphorum.com/news/roche-bulks-up-in-inflammation-with-e380m-inflazome-acquisition/

2nd Inflammasome Therapeutics Summit

2nd Inflammasome Therapeutics Summit

Targeting the Inflammasome

X

2nd Inflammasome Therapeutics Summit

https://pharmaphorum.com/events/2nd-inflammasome-therapeutics-summit/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com